Literature DB >> 15695917

Fenofibric acid.

Nigam P Rath1, Wahajul Haq, Ganesaratnam K Balendiran.   

Abstract

Unlike the related fenofibrate molecule [Henry, Zhang, Gao & Bruckner (2003). Acta Cryst. E59, o699-o700], fenofibric acid {systematic name: 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid}, C17H15ClO4, contains a carboxylic acid moiety instead of an ester moiety. This polar moiety plays an important role in the formation of a rare acid-to-ketone hydrogen-bond-type packing interaction. The lack of an isopropyl group in fenofibric acid aligns the carboxyl group on the same side as the ketone carbonyl group; this conformation may play an important role in discrimination between the acid and the fenofibrate molecule in molecular recognition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15695917     DOI: 10.1107/S0108270104032573

Source DB:  PubMed          Journal:  Acta Crystallogr C        ISSN: 0108-2701            Impact factor:   1.172


  13 in total

1.  2-Methyl-2-(4-nitro-phen-oxy)propanoic acid.

Authors:  Gabriel Navarrete-Vázquez; Hector Torres-Gómez; Sergio Hidalgo-Figueroa; Hugo Tlahuext
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-11-08

2.  Biomolecular chemistry of isopropyl fibrates.

Authors:  Ganesaratnam K Balendiran; Niharika Rath; Amanda Kotheimer; Chad Miller; Matthias Zeller; Nigam P Rath
Journal:  J Pharm Sci       Date:  2012-01-13       Impact factor: 3.534

3.  Fenofibrate but not fenofibric acid inhibits 11beta-hydroxysteroid dehydrogenase 1 in C2C12 myotubes.

Authors:  Chi Hyun Kim; Ravirala Ramu; Jin Hee Ahn; Myung Ae Bae; Young Sik Cho
Journal:  Mol Cell Biochem       Date:  2010-07-08       Impact factor: 3.396

4.  Molecular dynamics of fibric acids.

Authors:  Chad Miller; Steven Schildcrout; Howard Mettee; Ganesaratnam Balendiran
Journal:  Eur J Chem       Date:  2022-06-30

5.  2-Methyl-2-(4-nitro-phenyl-sulfanyl)-propanoic acid.

Authors:  Gabriel Navarrete-Vázquez; Rafael Villalobos-Molina; Samuel Estrada-Soto; Rolffy Ortiz-Andrade; Hugo Tlahuext
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2007-12-06

6.  Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.

Authors:  Malkhey Verma; Hans-Joerg Martin; Wahajul Haq; Timothy R O'Connor; Edmund Maser; Ganesaratnam K Balendiran
Journal:  Eur J Pharmacol       Date:  2008-02-05       Impact factor: 4.432

7.  Cancer biomarker AKR1B10 and carbonyl metabolism.

Authors:  Ganesaratnam K Balendiran; Hans-Joerg Martin; Yasser El-Hawari; Edmund Maser
Journal:  Chem Biol Interact       Date:  2008-11-05       Impact factor: 5.192

8.  Comparative In Vitro and In Vivo Evaluation of Fenofibric Acid as an Antihyperlipidemic Drug.

Authors:  Yulias Ninik Windriyati; Yeyet Cahyati Sumirtapura; Jessie Sofia Pamudji
Journal:  Turk J Pharm Sci       Date:  2020-04-24

Review 9.  Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.

Authors:  Elisavet Moutzouri; Anastazia Kei; Moses S Elisaf; Haralampos J Milionis
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

10.  Therapeutic Effects of PPARα Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration.

Authors:  Fangfang Qiu; Greg Matlock; Qian Chen; Kelu Zhou; Yanhong Du; Xiang Wang; Jian-Xing Ma
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-10-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.